Equities

CASI Pharmaceuticals Inc

CASI:NAQ

CASI Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.86
  • Today's Change0.404 / 11.68%
  • Shares traded29.67k
  • 1 Year change+37.02%
  • Beta0.5822
Data delayed at least 15 minutes, as of May 31 2024 20:59 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.

  • Revenue in USD (TTM)28.94m
  • Net income in USD-30.48m
  • Incorporated2023
  • Employees176.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Moolec Science SA2.65m-52.66m50.09m45.00--4.94--18.94-1.44-1.440.07660.2367------58,780.00--------2.92---1,990.79--0.2243-0.18890.2372-------1,044.02------
Lexaria Bioscience Corp404.72k-5.44m50.13m5.00--7.39--123.85-0.6851-0.68510.04930.52640.0722--1.6480,944.00-97.62-95.67-94.18-96.5895.6676.98-1,351.64-1,612.76---175.330.00---11.43-12.198.31------
Modular Medical Inc0.00-16.76m50.51m37.00--9.03-----0.9653-0.96530.000.18050.00----0.00-224.40-168.16-262.22-209.51------------0.00------25.51--154.53--
Kezar Life Sciences Inc7.00m-101.87m50.52m58.00--0.2693--7.22-1.40-1.400.09652.580.0269----120,689.70-39.12-32.54-41.41-34.09-----1,455.29-4,308.11----0.051-------49.28--10.08--
Ocean Biomedical Holdings Inc0.00-45.58m50.93m9.00---------1.40-1.400.00-0.0642------0.00-----------------------------612.50------
CASI Pharmaceuticals Inc28.94m-30.48m51.78m176.00--3.35--1.79-2.28-2.282.161.150.39541.003.41164,437.50-40.88-34.75-59.15-46.9158.3655.98-103.40-153.723.25-76.700.5458---21.41--34.27--14.65--
Carmell Corp0.00-18.29m51.80m9.00---------1.58-1.490.00-0.07190.00----0.00-428.46------58.60-------------------75.70------
Bright Green Corp0.00-11.46m52.24m5.00--4.70-----0.0631-0.06310.000.05840.00----0.00-56.05---84.87-------------18,125.840.0289------52.54------
IN8BIO, Inc.0.00-31.04m52.51m31.00--2.94-----0.9154-0.91540.000.40490.00----0.00-123.61-74.18-145.63-84.42------------0.0556-------5.21---4.54--
Equillium Inc37.89m-12.13m52.88m44.00--2.51--1.40-0.3476-0.34761.080.59830.6568--8.95861,227.30-21.02-46.81-39.66-57.36-----32.01-328.35----0.00--128.97--78.64--7.48--
DURECT Corp8.32m-23.28m53.08m48.00--6.39--6.38-0.8653-0.86530.29760.26740.1760.70216.87143,465.50-49.23-37.34-167.81-53.4480.5691.83-279.77-139.110.9575-47.700.6377---55.67-10.9621.82---10.98--
Anebulo Pharmaceuticals Inc0.00-9.35m53.16m2.00--10.66-----0.3633-0.36330.000.19220.00----0.00-91.51---104.28--------------0.00-------71.89------
Rockwell Medical Inc86.62m-8.42m53.20m237.00--2.51--0.6142-0.3584-0.35843.330.69841.9013.2810.12365,485.20-18.47-46.29-27.53-65.3810.594.66-9.72-36.511.38-3.540.331--14.845.6954.82--76.21--
Arca Biopharma Inc0.00-6.00m53.68m4.00--1.53-----0.4155-0.41550.002.420.00----0.00-15.24-27.78-15.81-29.38------------0.00------46.21------
Journey Medical Corp80.00m-4.16m54.65m58.00--6.00--0.6832-0.3095-0.30954.130.64980.9852.274.281,379,276.00-5.12---17.85--66.22---5.20--0.93570.40490.5773--7.48--87.00------
Data as of May 31 2024. Currency figures normalised to CASI Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

1.86%Per cent of shares held by top holders
HolderShares% Held
Wellington Shields Capital Management LLCas of 31 Mar 202492.22k0.69%
Wellington Shields & Co. LLC (Investment Management)as of 31 Mar 202443.09k0.32%
Howland Capital Management LLCas of 31 Mar 202440.43k0.30%
Renaissance Technologies LLCas of 31 Mar 202436.80k0.28%
Geode Capital Management LLCas of 31 Mar 202422.22k0.17%
Wells Fargo Clearing Services LLCas of 31 Mar 202412.01k0.09%
Morgan Stanley & Co. LLCas of 31 Mar 20241.38k0.01%
Simplex Trading LLCas of 31 Mar 2024623.000.01%
Fidelity Management & Research Co. LLCas of 31 Mar 2024500.000.00%
Dimensional Fund Advisors Ltd.as of 31 Mar 2024306.000.00%
More ▼
Data from 31 Mar 2024 - 23 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.